CoChat

The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome

Kakafika, Anna I., Mikhailidis, Dimitri P., Karagiannis, Asterios, Athyros, Vasilios G. · 2007 · The Journal of Clinical Pharmacology
Cited by 39

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

This review considers the use of the first selective blocker of the cannabinoid receptor type 1, rimonabant, to reduce weight and improve cardiovascular disease risk factors in obese patients with metabolic syndrome or multiple cardiovascular disease risk factors. In 4 large trials—Rimonabant in Obesity (RIO)–Lipids, RIO‐Europe, RIO–North America, and RIO‐Diabetes—after 1 to 2 years of treatment, rimonabant (20 mg/day) led to a significantly greater weight loss and reduction in waist circumference compared with placebo. Treatment with rimonabant was also associated with other favorable changes, including better glycemic control in type 2 diabetes mellitus, improved lipid profile, reduced blood pressure, increased adiponectin levels, fall in high‐sensitivity C‐reactive protein concentrations, and an overall decrease in the prevalence of the metabolic syndrome. Initial experience with rimonabant shows that it is generally well tolerated with the most common side effect of mild nausea. Rimonabant may be a useful adjunct to lifestyle and behavior modification in the treatment of obese subjects with metabolic syndrome or multiple cardiometabolic risk factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0091270007299358

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 39

Metadata

Authors
Kakafika, A. I., Mikhailidis, D. P., Karagiannis, A., & Athyros, V. G.
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2007-05
Volume
47
Issue
5
Pages
642-652
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
OpenAlex
W2115057047
Cited by
39
References
16
FWCI
5.09
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome. https://app.cochat.ai/papers/10.1177/0091270007299358
The paper
Kakafika, A. I., Mikhailidis, D. P., Karagiannis, A., & Athyros, V. G. (2007). The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270007299358

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.